Patents Assigned to AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
-
Patent number: 9856291Abstract: A synthetic peptide that targets cancer stem cells is provided. The peptide consists of the amino acid sequence of anyone of SEQ ID NO: 1 to SEQ ID NO: 15. Also provided is a composition comprising said synthetic peptide with a therapeutic agent fused thereto, and a pharmaceutically acceptable carrier or diluent. Further provided is a method of screening a peptide specifically targeting to a cancer stem cell. The method comprises the steps of establishing an oligopeptide library by using a phage expression system, contacting the library with a culture of bulk tumor cells of a cancer cell line, contacting the phages which do not bind to the bulk tumor cells with a culture of cancer stem cells of said cancer cell line, and screening a peptide specifically targeting to a cancer stem cell from the phages which bind to the cancer stem cells.Type: GrantFiled: December 8, 2016Date of Patent: January 2, 2018Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Chin-Kai Chuang, Yu-Hsyu Su, Tai-Yun Lin
-
Patent number: 9775893Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: March 8, 2017Date of Patent: October 3, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Patent number: 9757441Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: March 8, 2017Date of Patent: September 12, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Patent number: 9750790Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: December 19, 2016Date of Patent: September 5, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Patent number: 9750791Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: March 8, 2017Date of Patent: September 5, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Patent number: 9750792Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: March 8, 2017Date of Patent: September 5, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Patent number: 9730990Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: March 8, 2017Date of Patent: August 15, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Publication number: 20170202942Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: ApplicationFiled: March 8, 2017Publication date: July 20, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
-
Publication number: 20170196959Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: ApplicationFiled: March 8, 2017Publication date: July 13, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
-
Publication number: 20170182142Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better to immune effects.Type: ApplicationFiled: March 8, 2017Publication date: June 29, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
-
Publication number: 20170182144Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: ApplicationFiled: March 8, 2017Publication date: June 29, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
-
Publication number: 20170182143Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: ApplicationFiled: March 8, 2017Publication date: June 29, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
-
Patent number: 9683223Abstract: The present invention provides a ?-agarase, a composition containing the same and applications thereof. The present ?-agarase provides the field a novel alternative and is favorable for the industrial utilities of the hydrolysis products of agarose. Furthermore, the hydrolysis product of agarose by the present ?-agarase has high purity of neoagarotetraose therefore the present ?-agarase is especially useful for the neoagarotetraose's utilities in the field.Type: GrantFiled: July 25, 2016Date of Patent: June 20, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Zeng-Weng Chen, Hui-Jie Lin, Weng-Zeng Huang, Jian-Fong Lai, Shih-Ling Hsuan
-
Publication number: 20170158737Abstract: A synthetic peptide that targets cancer stem cells is provided. The peptide consists of the amino acid sequence of anyone of SEQ ID NO: 1 to SEQ ID NO: 15. Also provided is a composition comprising said synthetic peptide with a therapeutic agent fused thereto, and a pharmaceutically acceptable carrier or diluent. Further provided is a method of screening a peptide specifically targeting to a cancer stem cell. The method comprises the steps of establishing an oligopeptide library by using a phage expression system, contacting the library with a culture of bulk tumor cells of a cancer cell line, contacting the phages which do not bind to the bulk tumor cells with a culture of cancer stem cells of said cancer cell line, and screening a peptide specifically targeting to a cancer stem cell from the phages which bind to the cancer stem cells.Type: ApplicationFiled: December 8, 2016Publication date: June 8, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Chin-Kai CHUANG, Yu-Hsyu SU, Tai-Yun LIN
-
Publication number: 20170151318Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: ApplicationFiled: December 19, 2016Publication date: June 1, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
-
Publication number: 20170130217Abstract: The present invention provides a ?-agarase, a composition containing the same and applications thereof. The present ?-agarase provides the field a novel alternative and is favorable for the industrial utilities of the hydrolysis products of agarose. Furthermore, the hydrolysis product of agarose by the present ?-agarase has high purity of neoagarotetraose therefore the present ?-agarase is especially useful for the neoagarotetraose's utilities in the field.Type: ApplicationFiled: July 25, 2016Publication date: May 11, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Zeng-Weng CHEN, Hui-Jie LIN, Weng-Zeng HUANG, Jian-Fong LAI, Shih-Ling HSUAN
-
Patent number: 9561267Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: February 5, 2013Date of Patent: February 7, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Publication number: 20170002045Abstract: The present invention provides a plasmid, method and kit for producing heat labile enterotoxin B-subunit based on a Bacillus subtilis expression system. By comparing with the conventional method in the art, the present invention has the advantages of high safety, good yield, and simplified process and is therefore favorable for the commercialization object of heat labile enterotoxin B-subunit in the application of vaccine adjuvant.Type: ApplicationFiled: December 16, 2013Publication date: January 5, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Chien-Yu Fang, Zeng-Weng Chen, Ming-Wei Hsieh, Hao-Zhen Zeng, Jian-Fong Lai, Weng-Zeng Huang, Tzu-Ting Peng
-
Publication number: 20160264631Abstract: The present invention provides proteins that are suitable to be used as the active ingredient in subunit vaccine against Mycoplasma spp. The present invention also provides a subunit vaccine made therefrom. Said proteins have been experimentally proved to have the capability of inducing sufficient immune response to avoid pigs from Mycoplasma spp. infection. Said vaccine may have one of said proteins as active ingredient; or may have two or more of said proteins and is formulated as a cocktail vaccine. The present vaccine not only is safer than the conventional vaccines but also has equal or even better immune efficiency than the conventional ones. Furthermore, fusion partners suitable for producing said proteins of high solubility are also proved, which can significantly reduce production cost.Type: ApplicationFiled: November 21, 2013Publication date: September 15, 2016Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: JIUNN-HORNG LIN, JYH-PERNG WANG, ZENG-WENG CHEN, CHIEN-YU FANG, MING-WEI HSIEH, PING-CHENG YANG
-
Publication number: 20150366959Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: ApplicationFiled: February 5, 2013Publication date: December 24, 2015Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG